Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta-analysis of studies.

Omran J, Abdullah O, Abu-Fadel M, Gray WA, Firwana B, Drachman DE, Mahmud E, Aronow HD, White CJ, Al-Dadah AS.

Catheter Cardiovasc Interv. 2017 Mar 1;89(4):746-753. doi: 10.1002/ccd.26685. Epub 2016 Aug 16. Review.

PMID:
27526953
2.

Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention.

Barria Perez AE, Rao SV, Jolly SJ, Pancholy SB, Plourde G, Rimac G, Poirier Y, Costerousse O, Bertrand OF.

Am J Cardiol. 2016 Apr 15;117(8):1256-66. doi: 10.1016/j.amjcard.2016.01.015. Epub 2016 Jan 28. Review.

PMID:
26899489
3.

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis.

Li J, Yu S, Qian D, He Y, Jin J.

Medicine (Baltimore). 2015 Aug;94(32):e1067. doi: 10.1097/MD.0000000000001067. Review.

4.

Bivalirudin versus heparin in patients with acute myocardial infarction: A meta-analysis of randomized trials.

Ferrante G, Valgimigli M, Pagnotta P, Presbitero P.

Catheter Cardiovasc Interv. 2015 Sep;86(3):378-89. doi: 10.1002/ccd.25955. Epub 2015 Apr 24.

PMID:
25913723
5.

Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.

Ibebuogu UN, Bolorunduro O, Giri S, Dagogo-Jack S, Smith BG, Kar S, Reed GL.

Am J Cardiovasc Drugs. 2015 Aug;15(4):275-85. doi: 10.1007/s40256-015-0113-8. Erratum in: Am J Cardiovasc Drugs. 2015 Aug;15(4):287.

PMID:
25782437
6.

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW; BRIGHT Investigators.

JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.

PMID:
25775052
7.

Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.

Abtahian F, Waldo S, Jang IK.

Catheter Cardiovasc Interv. 2015 Sep;86(3):390-6. doi: 10.1002/ccd.25911. Epub 2015 Mar 30.

PMID:
25753749
8.

Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).

White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA.

JACC Cardiovasc Interv. 2015 Mar;8(3):424-33. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18.

9.

Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI.

Brener SJ, Ertelt K, Mehran R, Genereux P, Xu K, Witzenbichler B, Brodie BR, Guagliumi G, Stone GW.

Am Heart J. 2015 Feb;169(2):242-8. doi: 10.1016/j.ahj.2014.11.005. Epub 2014 Nov 12.

PMID:
25641533
10.

Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.

Stone GW, Mehran R, Goldstein P, Witzenbichler B, Van't Hof A, Guagliumi G, Hamm CW, Généreux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG.

J Am Coll Cardiol. 2015 Jan 6;65(1):27-38. doi: 10.1016/j.jacc.2014.10.029.

11.

Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?

Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG.

Am Heart J. 2014 Nov;168(5):611-21. doi: 10.1016/j.ahj.2014.06.014. Epub 2014 Jun 26. Review.

PMID:
25440788
12.

Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).

Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW.

Am J Cardiol. 2014 Dec 1;114(11):1638-45. doi: 10.1016/j.amjcard.2014.09.003. Epub 2014 Sep 18.

PMID:
25312637
13.

Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.

Sanborn TA, Tomey MI, Mehran R, Généreux P, Witzenbichler B, Brener SJ, Kirtane AJ, McAndrew TC, Kornowski R, Dudek D, Nikolsky E, Stone GW.

Catheter Cardiovasc Interv. 2015 Feb 15;85(3):371-9. doi: 10.1002/ccd.25663. Epub 2014 Oct 28.

PMID:
25179260
14.

Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.

Cavender MA, Sabatine MS.

Lancet. 2014 Aug 16;384(9943):599-606. doi: 10.1016/S0140-6736(14)61216-2.

PMID:
25131979
15.
16.

Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials.

Tarantini G, Brener SJ, Barioli A, Gratta A, Parodi G, Rossini R, Navarese EP, Niccoli G, Frigo AC, Musumeci G, Iliceto S, Stone GW.

Am Heart J. 2014 Mar;167(3):401-412.e6. doi: 10.1016/j.ahj.2013.11.013. Epub 2013 Dec 19.

PMID:
24576526
17.

The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.

Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW.

Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):67-77. doi: 10.1177/2048872613507149. Epub 2013 Oct 3.

18.

Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial.

Valgimigli M, Calabrò P, Cortese B, Frigoli E, Garducci S, Rubartelli P, Andò G, Santarelli A, Galli M, Garbo R, Repetto A, Ierna S, Briguori C, Limbruno U, Violini R, Gagnor A; MATRIX investigators.

J Cardiovasc Transl Res. 2014 Feb;7(1):101-11. doi: 10.1007/s12265-013-9537-1. Epub 2014 Jan 7.

PMID:
24395497
19.

Low-dose heparin for elective percutaneous coronary intervention.

Lee MS, Oyama J, Iqbal Z, Tarantini G.

J Interv Cardiol. 2014 Feb;27(1):58-62. doi: 10.1111/joic.12081. Epub 2013 Oct 24.

PMID:
24152197
20.

Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery.

Wöhrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, Grines C, McAndrew TC, Parise H, Sergie Z, Mehran R, Stone GW.

Am J Cardiol. 2013 Sep 15;112(6):753-60. doi: 10.1016/j.amjcard.2013.05.006. Epub 2013 Jun 6.

PMID:
23746479

Supplemental Content

Loading ...
Support Center